Avanza Fonder Ab Intellia Therapeutics, Inc. Transaction History
Avanza Fonder Ab
- $3.05 Trillion
- Q1 2025
A detailed history of Avanza Fonder Ab transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Avanza Fonder Ab holds 35,343 shares of NTLA stock, worth $298,294. This represents 0.01% of its overall portfolio holdings.
Number of Shares
35,343
Previous 36,065
2.0%
Holding current value
$298,294
Previous $421 Million
38.65%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding NTLA
# of Institutions
331Shares Held
95.4MCall Options Held
1.06MPut Options Held
863K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$110 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$86 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$81 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$43.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$32.2 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $642M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...